Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: A 21-month follow-up “real world” study

Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease

“…This is in accordance with results from studies identifying factors affecting ChEI treatment response (Pakrasi et al, 2003;Van der Putt et al, 2006;Caffarra et al, 2007;Calabria et al, 2009;Wallin et al, 2009), showing that patients with a lower baseline MMSE score were more likely to respond. One explanation may be that the MMSE is not able to detect an increase in MMSE score in patients with high MMSE scores, i.e.…”

“…Five Italian studies, all part of the Cronos project, investigated whether a cognitive response at three months predicted cognitive outcome (i.e. absolute MMSE score) at 9, 15, and 21 months (Mossello et al , 2004; Raschetti et al , 2005; Caffarra et al , 2007; Rota et al , 2007; Calabria et al , 2009). They showed that patients with a response at three months had a better cognitive outcome at all three endpoints than patients without a response (Mossello et al , 2004; Raschetti et al , 2005; Caffarra et al , 2007; Rota et al , 2007; Calabria et al , 2009).…”

CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer's Disease

“…Logistic regression models were used to estimate adjusted odds ratio (AOR) and 95% confidence intervals (CIs) for ChEI cognitive response in participants carrying 1 or 2 versus 0 copies of the minor allele of each SNP and each multilocus haplotype. Variables adjusted in the logistic regression models, e.g., age, baseline MMSE, APOE ε4 status, and hypertension history, were selected either by stepwise selection or because they were found to be important determinants of ChEI response in previous studies [36]-[38]. Type of ChEIs was not a significant determinant of treatment response, so this covariate was not adjusted in the final model.…”

Evaluation of acetylcholinesterase activity and behavioural alterations induced by ketamine in an animal model of schizophrenia

“…The AChE inhibitors are mainly used in the treatment of Alzheimer's disease. Although some efficacy on cognitive deficits, they do not change the course of the disease, and its role in the treatment of the disease is unclear (17). In addition, a recent meta-analysis has shown that que-specific cognitive deficits (memory, motor speed and attention) of patients with schizophrenia and schizoaffective disorder are responsive to rivastigmine, donepezil and galantamine (currently used AChE inhibitors in Alzheimer's disease), the adjunctive therapy.…”